Metsera, Inc. Common Stock (MTSR)

• Market cap: $3.09B
• 1 day: -15.04%
• 5 days: -7.03%
• 1 month: 12.57%
• 3 months: 21.10%
• 6 months: 10.87%
• Year to date: 10.87%
• 1 year: 10.87%
• 5 years: 10.87%
• 10 years: 10.87%
• Sector: Healthcare
• Industry: Biotechnology

About: Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.

Employees: 98

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

51.89% more ownership

Funds ownership: 0% [Q4 2024] → 51.89% (+51.89%) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $62 111% upside
• Avg. target: $62 111% upside
• High target: $62 111% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Guggenheim Evan Wang

111% upside $62

Buy Maintained

10 Jun 2025